Evaluating the Efficacy of Photobiomodulation Therapy in the Management of Chemotherapy-induced Peripheral Neuropathy: a Randomized Controlled Trial
Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This study aims to investigate the effectiveness of photobiomodulation therapy (PBM) in the management of chemotherapy-induced peripheral neuropathy (CIPN). Therefore, the hypothesis is that PBM can reduce the severity of CIPN in cancer patients, increasing the patient's quality of life.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Finished one of the following types of chemotherapy: paclitaxel, docetaxel, oxaliplatin, cisplatin, vincristine, thalidomide and/or bortezomib.
• Diagnosed with CIPN
• Age 18 years or above
• Have no documented or observable psychiatric or neurological disorders that might interfere with study participation (e.g., dementia or psychosis)
• Dutch-speaking
• Signed informed consent
Locations
Other Locations
Belgium
Jessa Hospital
RECRUITING
Hasselt
Contact Information
Primary
Jeroen Mebis, Prof. Dr.
jeroen.mebis@jessazh.be
011 33 72 21
Backup
Marithé Claes, MSc
marithe.claes@uhasselt.be
011 33 72 39
Time Frame
Start Date: 2023-03-27
Estimated Completion Date: 2030-03-15
Participants
Target number of participants: 172
Treatments
Experimental: Experimental: PBM1 group
The patients allocated to the first PBM-group will receive twelve PBM sessions of 6 J/cm² over six weeks (2x/week).
Experimental: Experimental: PBM2 group
The patients allocated to the second PBM-group will receive twelve PBM sessions of 8 J/cm² over six weeks (2x/week).
Related Therapeutic Areas
Sponsors
Leads: Jessa Hospital